|Year : 2019 | Volume
| Issue : 4 | Page : 157-159
Therapeutic hypothermia in stroke: Quo Vadis?
Mohammed A Almekhlafi1, Sven Poli2, Mayank Goyal1, Andrew M Demchuk1
1 Department of Clinical Neurosciences and Radiology, Calgary Stroke Program, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
2 Department of Neurology and Stroke, Hertie-Institute for Clinical Brain Research, Eberhard-Karls University of Tubingen, Tubingen, Germany
|Date of Submission||07-Dec-2019|
|Date of Decision||08-Dec-2019|
|Date of Acceptance||09-Dec-2019|
|Date of Web Publication||27-Dec-2019|
Dr. Mohammed A Almekhlafi
Department of Clinical Neurosciences and Radiology, Calgary Stroke Program, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Almekhlafi MA, Poli S, Goyal M, Demchuk AM. Therapeutic hypothermia in stroke: Quo Vadis?. Brain Circ 2019;5:157-9
Neuroprotection continues to be an elusive target despite numerous candidates. For decades, multiple promising compounds and strategies failed to translate encouraging experimental results into meaningful clinical benefits. Many therapies are still undergoing testing, while others are being refined or developed. This is particularly the case for neuroprotection in the acute ischemic stroke setting. The advent of endovascular thrombectomy has revived interest in neuroprotection. It awaits testing of when it should be administered: before/during/or after, fast and complete reperfusion. The ESCAPE-NA1 trial (NCT02930018), which has just completed recruitment, and PROOF (NCT03500939) trial will be the first to test promising neuroprotectants coupled with endovascular reperfusion.
Therapeutic hypothermia (TH) exceeds all other neuroprotective therapies in the wealth of robust evidence supporting its efficacy. Whether in experimental studies or at the bedside for postcardiac arrest patients or neonates with hypoxic-ischemic encephalopathy, TH demonstrates potent neuroprotective effects., Unfortunately, the benefits of TH have not been shown in ischemic stroke patients despite multiple trials. These trials have been criticized for the slow induction of TH after stroke onset; the use of various methods to induce systemic hypothermia, applied for different durations; and – most importantly – the inclusion of patients with varying volumes of infarct and reperfusion therapies. ICTuS 2/3 and, most recently, the EuroHYP-1 study had to be prematurely terminated due to slow recruitment (enrolled 120 and 98 of planned 1,600 and 1,500 patients, respectively), indicating low feasibility of the applied whole-body cooling in awake stroke patients., Both trials reported no benefit of TH compared to controls in improving 90-day functional outcome but also no significant differences in serious adverse events between the two trial arms. Pneumonia rates in TH patients (19% and 18%) trended to be twice as high compared to controls (11% and 4%, respectively).
These results prompted the search for better delivery methods to harness the benefits of TH while avoiding the potentially harmful effects of whole-body cooling and – at the same time – enhancing feasibility. Selective TH is promising to achieve these goals by targeting the brain, even the ischemic hemisphere, while sparing the rest of the body. Promising approaches include transnasal cooling, intra-arterial carotid infusion of chilled saline (open-loop cooling), closed-loop cooling using dual-lumen balloons and extracorporeal blood cooling, and transvenous retrograde cooling. Despite the quality evidence supporting selective TH from experimental studies, there are limited human studies., This issue represents an opportunity to inform the design of future trials of selective TH to avoid the pitfalls of systemic TH trials. Selective TH needs to be applied as soon as possible, ideally before reperfusion, but at least at the time of reperfusion or shortly after. It is paramount that these therapies can be smoothly incorporated into the workflow of acute stroke therapies without introducing reperfusion delays. Treatments should achieve rapid induction of brain cooling and maintain that for sufficient time, possibly hours. This may require combining more than one approach to facilitate cooling for longer durations, for example, hypothermia induction via an endovascular approach followed by a noninvasive maintenance approach. Future trials should aim to target patient population that is likely to benefit from TH. Those could include patients with a large ischemic core at baseline, those with inadequate collaterals, older patients, and those with expected delays to reperfusion, for example, transferred from distant centers.
This special issue of Brain Circulation attempts to highlight some of the opportunities and challenges of selective TH of the brain, mainly in the ischemic stroke setting. These articles highlight science and reviews from investigators who are actively working in the field of TH. The evidence for TH in stroke setting is discussed with attention to systemic versus selective approaches, and the methods to achieve that. The articles by Mattingly and Lownie and Cattaneo and Meckel, discuss different strategies for attaining intra-arterial selective TH via closed-loop cooling. This approach has the advantage of avoiding the volume overload from the infusion of chilled saline. However, the setting for the closed-loop system and the incorporation of these systems into stroke care pathway remains to be determined. Open-loop, intra-arterial infusion of chilled saline can be easily incorporated into the workflow of endovascular thrombectomy procedures. However, the article by Merrill et al. shows that significant warming occurs when chilled saline passes through the tubes and then via uninsulated catheters into the carotid artery when it warms further as it mixes with the blood. The infusate volume required to produce brain cooling and the resulting hemodilution are also factors to be considered when employing this approach. Transvenous selective retrograde brain cooling is another innovative approach that is promising to achieve rapid deep hypothermia. The target brain temperature needed to achieve neuroprotection is not well defined. Lyden et al. discuss moderate hypothermia (~33°C) which appears to provide better neuroprotection compared to mild hypothermia (35°C–37°C). This target temperature might be challenging to reach with noninvasive cooling methods. The investigators also perform some sample size calculations to show that a large clinical trial would be needed to demonstrate an outcome difference between mild and moderate hypothermia. Chen et al. propose using high-quality primate models, for example, cynomolgus macaques, before large-scale, randomized controlled trials are undertaken. Such studies could determine the safety and efficacy of various methods and target temperatures for TH using hyperacute imaging, novel biomarkers, and subsequent investigation of functional recovery. Finally, a word of caution regarding TH by Kalisvaart et al. summarizes the current evidence regarding the potential effects of various depths and durations of hypothermia on postinjury brain plasticity.
These articles do not cover all aspects related to TH. However, they raise important questions and attempt to solve important challenges relevant to all researchers interested in TH application in stroke setting. They will hopefully inform the design of future studies. Moreover, this work could facilitate the networking of groups that are interested in or actively working in the field of TH. The idea of this issue stemmed from such a networking event that included many of these issue contributors who attended the 1st Selective Hypothermia Symposium, which took place at the University of Calgary in March 2019. We hope that this issue will be an excellent opportunity for future collaboration and to keep the discussions ongoing.
Less than a decade ago, investigators struggled to show the benefits of endovascular thrombectomy in acute ischemic stroke. Subsequently, a flurry of positive trials came forward. What it took to achieve this was for investigators to select and enroll the optimal patient population and treat them fast, using safe and effective devices. We hope that neuroprotection trials will learn from the thrombectomy experience and follow the same path toward helping stroke patients.
| References|| |
Neuhaus AA, Couch Y, Hadley G, Buchan AM. Neuroprotection in stroke: The importance of collaboration and reproducibility. Brain 2017;140:2079-92.
Shi L, Rocha M, Leak RK, Zhao J, Bhatia TN, Mu H, et al
. A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion. J Cereb Blood Flow Metab 2018;38:2073-91.
van der Worp HB, Macleod MR, Kollmar R; European Stroke Research Network for Hypothermia (EuroHYP). Therapeutic hypothermia for acute ischemic stroke: Ready to start large randomized trials? J Cereb Blood Flow Metab 2010;30:1079-93.
Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al
. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N
Engl J Med 2002;346:557-63.
Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al
. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: Multicentre randomised trial. Lancet 2005;365:663-70.
Kuczynski A, Marzoughi S, Al Sultan AS, Goyal M, Demchuk A, Almekhlafi MA. Therapeutic hypothermia in patients with acute ischemic stroke a systematic review of prospective controlled studies. Stroke 2019;50:A83.
Winkel P, Bath PM, Gluud C, Lindschou J, van der Worp HB, Macleod MR, et al
. Statistical analysis plan for the EuroHYP-1 trial: European multicentre, randomised, phase III clinical trial of the therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute Ischaemic stroke. Trials 2017;18:573.
Lyden P, Hemmen T, Grotta J, Rapp K, Ernstrom K, Rzesiewicz T, et al
. Results of the ICTuS 2 Trial (intravascular cooling in the treatment of stroke 2). Stroke 2016;47:2888-95.
Esposito E, Ebner M, Ziemann U, Poli S. In cold blood: Intraarterial cold infusions for selective brain cooling in stroke. J Cereb Blood Flow Metab 2014;34:743-52.
Chen J, Liu L, Zhang H, Geng X, Jiao L, Li G, et al
. Endovascular hypothermia in acute ischemic stroke: Pilot study of selective intra-arterial cold saline infusion. Stroke 2016;47:1933-5.
Choi JH, Marshall RS, Neimark MA, Konstas AA, Lin E, Chiang YT, et al
. Selective brain cooling with endovascular intracarotid infusion of cold saline: A pilot feasibility study. AJNR Am J Neuroradiol 2010;31:928-34.
Sarraj A, Nogueira R, Liebeskind DS, Budzik R, Farrell CM, English J, et al
. Identifying patients who may benefit from thrombectomy in the late time window: Predictors of good outcome beyond advanced imaging. Stroke 2018;49:A112-A.
Huber C, Huber M, Ding Y. Evidence and opportunities of hypothermia in acute ischemic stroke: Clinical trials of systemic versus selective hypothermia. Brain Circ 2019:5:195-202.
Assis FR, Narasimhan B, Ziai W, Tandri H. From systemic to selective brain cooling – Methods in review. Brain Circ 2019:5;179-86.
Mattingly TK, Lownie SP. Cold blood perfusion for selective hypothermia in acute ischemic stroke. Brain Circ 2019:5;187-94.
Cattaneo G, Meckel S. Review of selective brain hypothermia in acute ischemic stroke therapy using an intracarotid, closed-loop cooling catheter. Brain Circ 2019:5;211-7.
Merrill TL, Smith B, Mitchell JE, Merrill DR, Pukenas B, Konstas A. Infusion warm during selective hypothermia in acute ischemic stroke. Brain Circ 2019:5;218-24.
Vaughan BC, Jones ME, Browne IL, Olshavsky JM, Schultz RD. Selective retrograde cerebral cooling in complete cerebral circulatory arrest. Brain Circ 2019:5;234-40.
Lyden P, Anderson A, Rajput P. Therapeutic hypothermia and type II errors: Don't throw out the baby with the ice water. Brain Circ 2019:5;203-10.
Chen Y, Quddusi A, Harrison KA, Ryan PE, Cook DJ. Selection of preclinical models to evaluate intranasal brain cooling for acute ischemic stroke. Brain Circ 2019:5;160-8.
Kurisu K, You J, Zheng Z, Won SJ, Swanson RA, Yenari MA. Cofilin actin rod formation in experimental stroke is attenuated by therapeutic hypothermia and overexpression of the inducible 70-kDa heat shock protein (Hsp70). Brain Circ 2019:5;225-33.
Kalisvaart A, Prokop B, Colbourne F. Hypothermia: Impact on plasticity following brain injury. Brain Circ 2019:5;169-78.
|This article has been cited by|
||Phenotype Shifting in Astrocytes Account for Benefits of Intra-Arterial Selective Cooling Infusion in Hypertensive Rats of Ischemic Stroke
| ||Luling Wang, Longfei Wu, Yunxia Duan, Shuaili Xu, Yuyao Yang, Jidong Yin, Ye Lang, Zongen Gao, Chuanjie Wu, Zaigang Lv, Jingfei Shi, Di Wu, Xunming Ji |
| ||Neurotherapeutics. 2022; |
|[Pubmed] | [DOI]|
||Therapeutic hypothermia in patients with poor-grade aneurysmal subarachnoid hemorrhage
| ||So Young Won, Mi Kyung Kim, Jihye Song, Yong Cheol Lim |
| ||Clinical Neurology and Neurosurgery. 2022; : 107369 |
|[Pubmed] | [DOI]|
||Selective intra-carotid blood cooling in acute ischemic stroke: A safety and feasibility study in an ovine stroke model
| ||Giorgio FM Cattaneo, Andrea M Herrmann, Sebastian A Eiden, Manuela Wieser, Elias Kellner, Soroush Doostkam, Patrick Süß, Selina Kiefer, Lisa Fauth, Christoph J Maurer, Julia Wolfertz, Björn Nitzsche, Michael Büchert, Tobias Jost, Gabriele Ihorst, Jörg Haberstroh, Christoph Mülling, Christoph Strecker, Wolf-Dirk Niesen, Mukesch J Shah, Horst Urbach, Johannes Boltze, Stephan Meckel |
| ||Journal of Cerebral Blood Flow & Metabolism. 2021; 41(11): 3097 |
|[Pubmed] | [DOI]|
||Phenothiazine Inhibits Neuroinflammation and Inflammasome Activation Independent of Hypothermia After Ischemic Stroke
| ||Sichao Guo,Xiaokun Geng,Hangil Lee,Yuchuan Ding |
| ||Molecular Neurobiology. 2021; |
|[Pubmed] | [DOI]|